Does Neoadjuvant Hormonal Therapy Improve Urinary Function When Given to Men With Large Prostates Undergoing Prostate Brachytherapy?

Journal of Urology

Volumn 183, Issue 2, 2010, Pages 634-640

  Stone, Nelson N ^a   Marshall, David T ^a   Stone, Jonathan J ^a   Cesaretti, Jamie A ^a   Stock, Richard G ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

agonists; brachytherapy; organ size; prostate; urinary retention

Indexed keywords

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BRACHYTHERAPY; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; TRANSURETHRAL RESECTION; URINE RETENTION;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; ORGAN SIZE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; URINARY RETENTION;

EID: 73749083914     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.09.084     Document Type: Article

References (26)

1. Kollmeier M.A., Stock R.G., and Stone N. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys 57 (2003) 645
2. Grimm P.D., Blasko J.C., Sylvester J.E., et al. 10-Year biochemical (prostate-specific antigen) control of prostate cancer with 125I brachytherapy. Int J Radiat Oncol Biol Phys 51 (2001) 31
3. Potters L., Morgenstern C., Calugaru E., et al. 12-Year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 173 (2005) 1562
4. Lee L.N., Stock R.G., and Stone N.N. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 52 (2002) 444
5. Ragde H. Radiotherapy for prostate cancer: brachytherapy alone. Urology 64 (2004) 631
6. Stock R.G., Cahlon O., Cesaretti J.A., et al. Combined modality treatment in the management of high-risk prostate cancer. Int J Radiat Oncol Biol Phys 59 (2004) 1352
7. Nag S., Beyer D., Friedland J., et al. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 44 (1999) 789
8. Koutrouvelis P.G., Lailas N., Katz S., et al. Prostate cancer with large glands treated with 3-dimensional computerized tomography guided pararectal brachytherapy: up to 8 years of followup. J Urol 169 (2003) 1331
9. Stone N.N., and Stock R.G. Prostate brachytherapy in patients with prostate volumes >/= 50 cm(3): dosimetric analysis of implant quality. Int J Radiat Oncol Biol Phys 46 (2000) 1199
10. Merrick G.S., Butler W.M., Wallner K.E., et al. The effect of hormonal manipulation on urinary function following permanent prostate brachytherapy. Brachytherapy 3 (2004) 22
11. Locke J., Ellis W., Wallner K., et al. Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: a prospective study. Int J Radiat Oncol Biol Phys 52 (2002) 712
12. Kang S.K., Chou R.H., Dodge R.K., et al. Acute urinary toxicity following transperineal prostate brachytherapy using a modified Quimby loading method. Int J Radiat Oncol Biol Phys 50 (2001) 937
13. Crook J., McLean M., Catton C., et al. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 52 (2002) 453
14. Terk M.D., Stock R.G., and Stone N.N. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol 160 (1998) 1379
15. Stock R.G., Stone N.N., Wesson M.F., et al. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys 32 (1995) 219
16. Stock R.G., Stone N.N., Cesaretti J.A., et al. Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys 64 (2006) 527
17. Stone N.N., and Stock R.G. Prospective long-term analysis of urinary symptoms and quality of life in men with large or small prostates treated with prostate brachytherapy. Brachytherapy 2 (2003) 32
18. Bucci J., Morris W.J., Keyes M., et al. Predictive factors of urinary retention following prostate brachytherapy. Int J Radiat Oncol Biol Phys 53 (2002) 91
19. Landis D.M., Schultz D., Cormack R., et al. Acute urinary retention after magnetic resonance image-guided prostate brachytherapy with and without neoadjuvant external beam radiotherapy. Urology 65 (2005) 750
20. Keyes M., Schellenberg D., Moravan V., et al. Decline in urinary retention incidence in 805 patients after prostate brachytherapy: the effect of learning curve?. Int J Radiat Oncol Biol Phys 64 (2006) 825
21. Gutman S., Merrick G.S., Butler W.M., et al. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy. BJU Int 97 (2006) 62
22. Keyes M., Miller S., Morovan V., et al. Predicitve factors for acute and late urinary toxicity active permanent prostate brachytherapy: long-term outcome in 712 consecutive patients. Int J Radiat Oncol Biol Phys 73 (2009) 1023
23. Hinerman-Mulroy A., Merrick G.S., Butler W.M., et al. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 59 (2004) 1367
24. Stone N.N. Ultrasound determination of prostate volume: a comparison of transrectal (ellipsoid versus planimetry) and suprapubic methods. J Endourol 5 (1991) 251
25. Beyer D.C., McKeough T., and Thomas T. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 61 (2005) 1299
26. Stone N.N., Potters L., Davis B.J., et al. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 73 (2009) 341